Servier to acquire Day One for $2.5B

The deal's centerpiece is a glioma drug that won U.S. approval in 2024 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

March 6, 2026 Check out STAT+

Sponsored By

Good morning. Angus Chen, STAT's cancer reporter, here. Metastasis is a turning point in cancer. For many diseases, the moment a satellite tumor takes hold in the body is when cancer is considered to be incurable, but scientists know relatively little about how metastasis happens. An in vitro study published in Nature on Wednesday suggests that activation of the glucocorticoid receptor in breast cancer cells might be a key step that these cancer cells take to avoid the immune system when metastasizing. The work, led by Judith Agudo from Dana-Farber, seems to suggest that activation of this receptor downregulates a key cell death protein called FAS. This protein can signal T cells and get the immune system to essentially order the cell to kill itself. By taking away this protein, glucocorticoid receptor activation might help cancer cells survive better and evade immune killing. This is really interesting work to me, since metastasis isn't well understood, and it helps to elucidate another piece of biology around the tenuous balance between the immune system and cancer. Getting to the heart of mechanisms that allow metastasis to occur might also be crucial to preventing patients from dying.

Adobe STAT+ | Servier to acquire Day One, maker of pediatric cancer drug, for $2.5B The deal's centerpiece is Day One's Ojemda, which won U.S. approval in 2024 as a treatment for pediatric low-grade glioma. By Andrew Joseph Opinion: CMS shouldn't be paying for higher-than-necessary doses of cancer drugs CMS could help patients and taxpayers by only paying for oncology drug dosages that are reasonable and necessary. By Mark J. Ratain and David A. Hyman How the 'holy grail' weight loss pill became a reality, and what comes next Take a medicine in a syringe and put it in pill form. Sounds easy, right? STATus Report host Alex Hogan examines a new era of GLP-1 drugs. By Alex Hogan SAUL LOEB / AFP via Getty Images A month in, TrumpRx falls short of president's grand promises Visits appear to be lagging, few drugs have been added, and some deals with pharma companies are still being worked out. By Daniel Payne

More around STAT

---

In case you missed it ExThera Medical attracted cancer patients to Antigua with the promise that its devices could cure them. Its former chief regulatory officer faces up to three years in prison, New York Times How 10-minute procedures and routine scans become five-figure medical bills, Washington Post Tackling air pollution should be part of government work to cut cancer rates, scientists say, the Guardian

---

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2026, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser